Page d'accueil  |  Aide  |  Effacer
Anglais  |  Français
 Rechercher  |  Catégories  |  Titres A-Z  |  Pays  |  Comparer pays  |  Index  
Etendre sommaire
Document complet
Dérouler chapitre
Préférences

fermer ce livreDrugs Formulary for District Hospitals - Ethiopia (DACA; 2004; 322 pages)
Afficher le documentACKNOWLEDGEMENTS
Afficher le documentINTRODUCTION
Afficher le documentGENERAL ADVICE TO PRESCRIBERS
ouvrir ce répertoire et afficher son contenu1. DRUGS ACTING ON THE GASTROINTESTINAL SYSTEM
ouvrir ce répertoire et afficher son contenu2. CARDIOVASCULAR DRUGS
ouvrir ce répertoire et afficher son contenu3. RESPIRATORY DRUGS
ouvrir ce répertoire et afficher son contenu4. CENTRAL NERVOUS SYSTEM DRUGS
ouvrir ce répertoire et afficher son contenu5. DRUGS USED IN ANESTHESIA
ouvrir ce répertoire et afficher son contenu6. DRUGS USED IN MUSCLOSKELETAL AND JOINT DISEASE
fermer ce répertoire7. ANTI-INFECTIVE
ouvrir ce répertoire et afficher son contenu7.1. Antibacterials
Afficher le document7.2. Antifungals
Afficher le document7.3. Antiviral
fermer ce répertoire7.4. Antiprotozoals
Afficher le document7.4.1 Antimalarials
Afficher le document7.4.2. Amoebicides and Antigiardial Agents.
Afficher le document7.4.3. Leshmaniacides
Afficher le document7.4.4. Trypanocides
Afficher le document7.4.5. Drugs for Toxoplasmosis
ouvrir ce répertoire et afficher son contenu7.5. Anthelmintics
ouvrir ce répertoire et afficher son contenu8. DRUGS USED IN ENDOCRINE DISORDERS AND CONTRACEPTIVES.
Afficher le document9. OBSTETRIC AND GYNAECOLOGICAL MEDICATIONS
ouvrir ce répertoire et afficher son contenu10. BLOOD PRODUCTS AND DRUGS AFFECTING THE BLOOD
ouvrir ce répertoire et afficher son contenu11. DRUGS FOR CORRECTING WATER, ELECTROLYTE AND ACID - BASE DISTURBANCES
ouvrir ce répertoire et afficher son contenu12. VITAMINS
ouvrir ce répertoire et afficher son contenu13. ANTIHISTAMINES AND ANTIALLERGICS
ouvrir ce répertoire et afficher son contenu14. OPHTHALMIC AGENTS
ouvrir ce répertoire et afficher son contenu15. EAR, NOSE, AND THROAT PREPARATIONS
ouvrir ce répertoire et afficher son contenu16. DERMATOLOGIC AGENTS
Afficher le document17. ANTIDOTES AND OTHER SUBSTANCES USED IN POISONING
Afficher le document18. IMMUNOLOGICAL PREPARATIONS
Afficher le document19. MISCELLANEOUS
Afficher le documentAPPENDIXES
Afficher le documentGLOSSARY
Afficher le documentBACK COVER
 

7.4.5. Drugs for Toxoplasmosis

Toxoplasmosis is caused by infection with the protozoan parasite Toxoplasma gondii. Toxoplasmosis in immunocompetent individuals is usually asymptomatic and if symptomatic infection does occur it is usually self-limiting. Very rarely myocarditis or encephalitis may occur. Patients with impaired immunity may develop serious complications such as encephalitis, myocarditis, and pneumonitis.

The treatment of choice is a combination of pyrimethamine and sulphadiazine. Calcium folinate should also be given every third day during treatment to counteract megaloblastic anaemia. Treatment is ideally continued for several weeks after clinical cure. Prolonged even life long, maintenance therapy should be considered for AIDS patients since the tissue cyst forms of T.gondii will not have been affected by the initial treatment.

Congenital toxoplasmosis is not a problem in women who have toxoplasma antibody before conception but primary toxoplasmosis during early pregnancy is serious because of the risk of transplacental transmission, which may result in foetal death or congenital toxoplasmosis.

Pyrimethamine
Tablet, 25mg

Indications: - pyrimethamine is indicated in combination with sulfapyrimedine - type sulfonamide in the treatment of toxoplasmosis caused by Toxoplasma gondii.

Cautions: - pregnancy and breast-feeding, hepatic function impairment and in those patients hypersensitive to pyrimethamine.

Drug interactions - bone marrow depressants, folate antagonists.

Contraindications - pregnancy (14 or 16 weeks), hypersensitivity, history of seizures disorders, anaemia and bone marrow depression.

Side effects: - Atrophic glossitis (pain, burning, or inflammation of the tongue, change in or loss of taste), blood dyscrasias, specifically agranulocytosis (fever, sore throat), megaloblastic anaemia (unusual tiredness, or weakness), or thrombocytopenia (unusual bleeding or bruising), GIT disturbance (anorexia, Nausea, vomiting, diarrhoea), Hypersensitivity (skin rash).

Dose and Administration:

Toxoplasmosis (in second and third trimesters of pregnancy), by mouth, adult 25mg daily for 3-4 weeks

Toxoplasmosis in NEONATES, by mouth, 1 mg/kg daily; duration of treatment depends on whether neonate has overt disease-continue for 6 months, or is without overt disease but, born to mother infected during pregnancy-treat for 4 weeks, followed by further courses if infection confirmed.

Toxoplasmosis in immunodeficiency, by mouth, Adult, 200mg in divided doses on first day, then 75-100mg daily for at least 6 weeks, followed by a suppressive dose of 25-50mg daily.

Chorioretinitis, by mouth, Adult 75mg daily for 3 days then 25mg daily for 4 weeks; in unresponsive patients, 50 mg daily for a further 4 weeks

Note: for the treatment of toxoplasmosis, pyrimethamine must always be taken with sulfadiazine. Take with meals and continue medicine with full time of treatment.

Storage: - at room temperature in a tight, light-resistant container.

Sulphadiazine
Tablet, 500mg

Indications: - toxoplasmosis (with pyrimethamine); rheumatic fever

Cautions: - hepatic and renal impairment; maintain adequate fluid intake (to avoid crystalluria); avoid in blood disorders (unless under specialist supervision); monitor blood counts and discontinue immediately if blood disorder develops; rashes - discontinue immediately; elderly; asthma, G6PD deficiency; pregnancy - avoid in first trimester, but may be given thereafter if danger of congenital transmission; breast feeding; see also interactions.

Drug interactions: - ciclosporin, glibenclamide, pyrimethamine & co-trimoxazole (increased risk of antifolate effect), Warfarin

Contraindications: - hypersensitivity to sulfonamides, severe renal failure or severe hepatic impairment, porphyria.

Side effects: - nausea, vomiting, diarrhea, headache, hypersensitivity reactions including rashes, pruritus, photosensitivity reactions, exfoliative dermatitis, and erthema nodosum; rarely, erythemamultiforme and toxic epidermal necrolysis; crystalluria resulting in haematuria, oliguria, anuria, blood disorders including granulocytopenia, agranulocytosis, aplastic anaemia, purpura - discontinue immediately, liver damage, pancreatitis, antibiotic - associated colitis, eosinophilia, cough and shortness of breath, pulmonary infiltrates, aseptic meningitis, depression, convulsions, ataxia, tinnitus, and electrolyte disturbances.

Dose and Administrations: -

Toxoplasmosis (in second and third trimesters of pregnancy), by mouth, Adult 3g daily in 4 divided doses.

Toxoplasmosis in neonates, by mouth, 85mg/kg daily in 2 divided doses; duration of treatment depends on whether the neonate has overt disease continue for 6 months, or is without overt disease but born to mother infected during pregnancy - treat for 4 weeks, followed by further courses, if infection confirmed.

Toxoplasmosis in immunodeficiency, by mouth, Adult, 4 - 6g daily in 4 divided doses for at least 6 weeks followed by a suppressive dose of 2 - 4g daily.

Note: - For the treatment of toxoplasmosis, Sulfadiazine must always be taken with pyrimethamine.

Storage: - below 30°C in a tight container, protect from light.

vers la section précédentevers la section suivante

S'il vous plaît envoyez vos commentaires Anglais  |  Français